SEATTLE--(BUSINESS WIRE)--TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead. Glynn Wilson TapImmune’s CEO provided insights in an interview on the floor of the NASDAQ recently which can be seen by navigating to the following link:
Help employers find you! Check out all the jobs and post your resume.
